Literature DB >> 15242525

Enhanced transgene expression in quiescent and activated human CD8+ T cells.

Laurence J N Cooper1, Max S Topp, Cris Pinzon, Ivan Plavec, Michael C Jensen, Stanley R Riddell, Philip D Greenberg.   

Abstract

The level of expression of retroviral vector-encoded proteins in T cells, decreasing during periods of quiescence, could be an obstacle to their clinical utility. To identify promoter systems that could increase the strength and persistence of transgene expression in primary human CD8(+) T cells, we designed a panel of Moloney retroviral vectors to express a destabilized enhanced green fluorescent protein (d4EGFP) reporter protein (t(1/2) = 4 hr). We found that the promoters phosphoglycerate kinase (Pgk), beta-actin, and long terminal repeat (LTR) produced the highest levels of d4EGFP expression in proliferating T cells, but that expression dramatically declined in quiescent cells with all promoters. To improve gene expression, we examined the effect of the beta-interferon (IFN) scaffold attachment region (SAR). This SAR augmented expression from mammalian promoters in cycling T cells, but had a small effect on maintenance of expression in resting T cells. However, when the SAR was combined with the LTR promoter, it significantly enhanced expression in resting and cycling cells. These data support use of the IFN-beta SAR with the LTR in Moloney retroviral vectors to help sustain gene expression in resting primary human CD8(+) T cells and to enhance gene expression in activated T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242525     DOI: 10.1089/1043034041361217

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

Authors:  Marleen M van Loenen; Renate de Boer; Ellis van Liempt; Pauline Meij; Inge Jedema; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

Review 4.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  T-cell receptor gene therapy of established tumors in a murine melanoma model.

Authors:  John D Abad; Claudia Wrzensinski; Willem Overwijk; Moniek A De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille J Cohen; Chrystal M Paulos; Douglas C Palmer; John B A G Haanen; Ton N M Schumacher; Steven A Rosenberg; Nicholas P Restifo; Richard A Morgan
Journal:  J Immunother       Date:  2008-01       Impact factor: 4.456

Review 6.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

7.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

8.  Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

Authors:  S Yang; C J Cohen; P D Peng; Y Zhao; L Cassard; Z Yu; Z Zheng; S Jones; N P Restifo; S A Rosenberg; R A Morgan
Journal:  Gene Ther       Date:  2008-05-22       Impact factor: 5.250

9.  Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR.

Authors:  Michelle L Dossett; Ryan M Teague; Thomas M Schmitt; Xiaoxia Tan; Laurence Jn Cooper; Cristina Pinzon; Philip D Greenberg
Journal:  Mol Ther       Date:  2009-02-10       Impact factor: 11.454

10.  Expression-independent gene trap vectors for random and targeted mutagenesis in embryonic stem cells.

Authors:  Anestis Tsakiridis; Elena Tzouanacou; Afifah Rahman; Douglas Colby; Richard Axton; Ian Chambers; Valerie Wilson; Lesley Forrester; Joshua M Brickman
Journal:  Nucleic Acids Res       Date:  2009-08-19       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.